Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

5,416JPY
12:03am EST
Change (% chg)

¥196 (+3.75%)
Prev Close
¥5,220
Open
¥5,278
Day's High
¥5,417
Day's Low
¥5,268
Volume
1,256,000
Avg. Vol
1,919,802
52-wk High
¥5,418
52-wk Low
¥3,694

4523.T

Chart for 4523.T

About

Eisai Co., Ltd. is mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of drugs for pharmaceutical, over-the-counter and diagnostic uses. The Others segment manufactures and... (more)

Overall

Beta: 0.33
Market Cap(Mil.): ¥1,530,582.00
Shares Outstanding(Mil.): 296.57
Dividend: 80.00
Yield (%): 2.91

Financials

  4523.T Industry Sector
P/E (TTM): 93.76 40.21 40.82
EPS (TTM): 55.05 -- --
ROI: 2.09 19.07 18.35
ROE: 3.05 19.85 19.25
Search Stocks

BRIEF-Oncodesign enters into services agreement with Eisai

* Says it has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

17 Dec 2014

BRIEF-Hikma Pharma says in partnership with Eisai for epilepsy treatment drug

* Hikma Enters Partnership With Eisai For Distribution Of First-in-class Epilepsy Treatment Fycompa In Middle East

13 Oct 2014

FDA approves Eisai drug for chemotherapy-associated nausea

- The U.S. Food and Drug Administration said on Friday it has approved Japanese pharmaceutical company Eisai's drug Akynzeo to treat nausea and vomiting in patients undergoing chemotherapy for cancer.

10 Oct 2014

FDA approves Eisai drug for chemotherapy-associated nausea

Oct 10 - The U.S. Food and Drug Administration said on Friday it has approved Japanese pharmaceutical company Eisai's drug Akynzeo to treat nausea and vomiting in patients undergoing chemotherapy for cancer.

10 Oct 2014

Long-awaited diet pill gets U.S. approval

- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

11 Sep 2014

Long-awaited diet pill gets U.S. approval

- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

10 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks